ezetimibe has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 16 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) | Trials ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) | Recent Studies (post-2010) ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 1,459 | 368 | 396 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Császár, A; Márk, L | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Cutler, DL; Kosoglou, T; Maxwell, S; Reyderman, L; Statkevich, P | 1 |
| Heemann, U; Kohnle, M; Kribben, A; Philipp, T; Pietruck, F; Witzke, O | 1 |
| Alonso-Villaverde, C; Aragonés, G; Coll, B; Masana, L; Parra, S | 1 |
| Ballantyne, CM; Gimpelewicz, CR; Seper, C; Sirnes, PA; Stein, EA; Sussekov, A; Windler, E; Yigit, Z | 1 |
| Alvarez-Sala, LA; Cachofeiro, V; Gambus, G; Lahera, V; Masana, L; Moreno, MA; Pinilla, B; Pintó, X; Plana, N; Suarez, C; Trias, F | 1 |
| Doggrell, SA | 1 |
| Abletshauser, C; Geisen, U; Hoffmann, MM; Odünc, N; Pütz, G; Schäfer, G; Schewe, T; Siegel, E; Winkler, K | 1 |
| Visseren, FL; Westerink, J | 1 |
| de Campo, A; März, W; Scharnagl, H; Schmölzer, I; Sourij, H; Stojakovic, T; Wascher, TC | 1 |
| Aoki, C; Hattori, Y; Iijima, T; Jojima, T; Kasai, K; Kase, H; Kawagoe, Y; Nakano, A; Ohta, S; Tanaka, S; Tomizawa, A | 1 |
| Parhofer, KG | 1 |
| Bokuda, K; Ichihara, A; Itoh, H; Kinouchi, K; Morimoto, S | 1 |
| Asakura, Y; Habara, M; Ito, T; Kimura, M; Kinoshita, Y; Ko, E; Kurita, T; Matsubara, T; Nasu, K; Suzuki, T; Teramoto, T; Terashima, M; Tsuchikane, E; Yokota, D | 1 |
| Macchi, C; Magni, P; Morlotti, B; Ruscica, M; Sirtori, CR | 1 |
3 review(s) available for ezetimibe and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Risk identification and possible countermeasures for muscle adverse effects during statin therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Colesevelam Hydrochloride; Creatine Kinase; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Muscular Diseases; Myalgia; Rhabdomyolysis; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sex Factors; Vitamin D Deficiency | 2015 |
11 trial(s) available for ezetimibe and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged | 2005 |
Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cyclosporine; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Kidney Transplantation; Liver; Male; Middle Aged; Muscle, Skeletal; Pravastatin; Simvastatin; Tacrolimus | 2006 |
Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Azetidines; Cholesterol; Cholesterol, LDL; Endothelium; Ezetimibe; Fatty Acids, Monounsaturated; Fluvastatin; HIV-Associated Lipodystrophy Syndrome; Humans; Indoles; Treatment Outcome | 2006 |
Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Male; Middle Aged; Muscular Diseases; Treatment Outcome; Triglycerides | 2008 |
Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-labe
Topics: Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Interleukin-1beta; Male; Middle Aged; Triglycerides | 2008 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Humans; Indoles; Male; Metabolic Syndrome; Middle Aged; Simvastatin; Treatment Outcome | 2009 |
Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Indoles; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies | 2010 |
Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Indoles; Male; Middle Aged; Treatment Outcome; Triglycerides; Vasodilation | 2011 |
Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial.
Topics: Adult; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hypercholesterolemia; Indoles; Kidney Function Tests; Male; Middle Aged | 2013 |
Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Tomography, Optical Coherence | 2014 |
2 other study(ies) available for ezetimibe and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hypolipidemic Agents; Indoles; Metabolic Syndrome; Simvastatin | 2010 |
[After bypass surgery nearly all lipids are in the normal range. However, Lp(a) is too high, what can be done?].
Topics: Azetidines; Cholesterol; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Lipoprotein(a); Male; Postoperative Complications; Prognosis; Reference Values; Risk Factors; Secondary Prevention; Treatment Outcome | 2011 |